Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia
An Open-label, Single-arm, Single-center Study to Evaluate the Efficacy and Safety of Romiplostim N01 in Combination With Rituximab in Patients With Primary Immune Thrombocytopenia Refractory to Oral TPO-RAs
Sponsor: The First Affiliated Hospital of Soochow University
A NA clinical study on Primacy Immune Thrombocytopenia, this trial is actively recruiting participants. The trial is conducted by The First Affiliated Hospital of Soochow University and has accumulated 2 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
2 versions recorded-
Jan 2026 — Present [monthly]
Recruiting NA
-
Nov 2025 — Jan 2026 [monthly]
Recruiting NA
First recorded
Sep 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The First Affiliated Hospital of Soochow University
For direct contact, visit the study record on ClinicalTrials.gov .